olmesartan medoxomil has been researched along with risperidone in 3 studies
Studies (olmesartan medoxomil) | Trials (olmesartan medoxomil) | Recent Studies (post-2010) (olmesartan medoxomil) | Studies (risperidone) | Trials (risperidone) | Recent Studies (post-2010) (risperidone) |
---|---|---|---|---|---|
459 | 119 | 203 | 6,924 | 1,505 | 2,477 |
Protein | Taxonomy | olmesartan medoxomil (IC50) | risperidone (IC50) |
---|---|---|---|
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.015 | |
5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0027 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0097 | |
Cytochrome P450 2D6 | Homo sapiens (human) | 5.2734 | |
Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 4.1901 | |
D(2) dopamine receptor | Homo sapiens (human) | 0.0167 | |
5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0991 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.026 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0096 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.799 | |
D(1A) dopamine receptor | Homo sapiens (human) | 0.479 | |
Histamine H2 receptor | Homo sapiens (human) | 1.483 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.01 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0016 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0057 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.799 | |
5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0027 | |
5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | 0.0015 | |
Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.0105 | |
5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | 0.0015 | |
Histamine H1 receptor | Homo sapiens (human) | 0.4515 | |
D(3) dopamine receptor | Homo sapiens (human) | 0.024 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.023 | |
D(2) dopamine receptor | Mus musculus (house mouse) | 0.023 | |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0154 | |
5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | 0.0015 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.6303 | |
5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 0.43 | |
Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 4.1901 | |
Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 1.6 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for olmesartan medoxomil and risperidone
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for olmesartan medoxomil and risperidone
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |